Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Pfizer commits to UK research hub in AstraZeneca battle

Published 02/05/2014, 07:22
Updated 02/05/2014, 07:32
PFE
-

LONDON (Reuters) - U.S. pharmaceutical group Pfizer Inc (N:PFE) has told Prime Minister David Cameron it will retain British jobs and a planned scientific research hub in Cambridge if it succeeds in its bid to take over rival AstraZeneca .

Pfizer laid out a number of pledges in a letter to Cameron, including establishing the combined company's corporate and tax residence in England and completing a substantial R&D innovation hub in Cambridge, eastern England.

Pfizer also vowed that 20 percent of the combined company's total R&D workforce would be in Britain if the deal goes ahead.

"We would like to assure the government of our long term commitment to the UK where Pfizer already employs a significant number of colleagues across Research, Commercial, and Administrative roles," the company said on Friday.

(Reporting by Paul Sandle; editing by Kate Holton)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.